305 results on '"Schnitzer, T."'
Search Results
2. OP0251 DURATION OF CLINICALLY MEANINGFUL ANALGESIC RESPONSE TO INTRA-ARTICULAR MM-II, A NOVEL SUSPENSION OF LARGE, EMPTY, MULTILAMELLAR LIPOSOMES, IN PATIENTS WITH PAINFUL KNEE OSTEOARTHRITIS: ANALYSIS FROM A 26-WEEK PHASE 2B RANDOMISED CONTROLLED TRIAL
3. POS0106 INTRA-ARTICULAR MM-II, A NOVEL SUSPENSION OF LARGE EMPTY MULTILAMELLAR LIPOSOMES, IN PAINFUL KNEE OSTEOARTHRITIS: A 26 WEEK PHASE 2B RANDOMIZED TRIAL
4. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
5. Evaluation of S201086/GLPG1972, an ADAMTS-5 inhibitor, for the treatment of knee osteoarthritis in ROCCELLA:a phase 2 randomized clinical trial
6. OARSI Clinical Trials Recommendations: Design, conduct, and reporting of clinical trials for knee osteoarthritis
7. Comparison of Finite Volume and Discontinuous Galerkin Methods of Higher Order for Systems of Conservation Laws in Multiple Space Dimensions
8. Bone mineral and stiffness loss at the distal femur and proximal tibia in acute spinal cord injury
9. The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial
10. Bone mineral loss at the proximal femur in acute spinal cord injury
11. Tanezumab for the treatment of pain from osteoarthritis of the knee.
12. Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis
13. FRI0392 ADVERSE EVENTS IN PATIENTS WITH OSTEOARTHRITIS TREATED WITH SUBCUTANEOUS TANEZUMAB: A POOLED ANALYSIS OF THE OVERALL POPULATION AND SELECTED SUBGROUPS FROM 3 RANDOMISED PLACEBO-CONTROLLED TRIALS
14. FRI0378 GENERAL SAFETY AND TOLERABILITY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF OSTEOARTHRITIS: A POOLED ANALYSIS OF RANDOMIZED, PLACEBO-CONTROLLED TRIALS
15. OP0090 EFFICACY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF CHRONIC LOW BACK PAIN: AN ANALYSIS OF BRIEF PAIN INVENTORY-SHORT FORM SCORES FROM A 56-WEEK, RANDOMIZED, PLACEBO- AND TRAMADOL-CONTROLLED, PHASE 3 TRIAL
16. Change in regional cartilage morphology and joint space width in osteoarthritis participants versus healthy controls: a multicentre study using 3.0 Tesla MRI and Lyon–Schuss radiography
17. Investigation of the maturation and assembly of vesicular stomatitis virus and its phenotypic mixing with other viruses
18. Precision of 3.0 Tesla quantitative magnetic resonance imaging of cartilage morphology in a multicentre clinical trial
19. Head-to-head comparison of the Lyon Schuss and fixed flexion radiographic techniques. Long-term reproducibility in normal knees and sensitivity to change in osteoarthritic knees
20. Incidence of Nonvertebral Fractures in Relation to Time on Treatment and Bone Density in Glucocorticoid-Treated Patients: A Retrospective Approach
21. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis
22. A Randomized, Double-Blind, Crossover Clinical Trial of Diclofenac Plus Misoprostol Versus Acetaminophen in Patients With Osteoarthritis of the Hip or Knee
23. Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women*
24. Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip
25. Characterizing pain and relief after joint replacement in hip and knee osteoarthritis
26. Hyperbolic Divergence Cleaning for the MHD Equations
27. SAT0575 Safety and efficacy of lutikizumab (ABT-981), an anti–interleukin-1 alpha/beta dual variable domain (DVD) immunoglobulin, in subjects with knee osteoarthritis: results from the randomised, double-blind, placebo-controlled, parallel-group phase 2 trial
28. INTRA-ARTICULAR MM-II, A NOVEL SUSPENSION OF LARGE EMPTY MULTILAMELLAR LIPOSOMES, IN PAINFUL KNEE OSTEOARTHRITIS: A 26 WEEK PHASE 2B RANDOMIZED TRIAL.
29. Viral Replication in Lymphocytes and the Pathogenesis of Connective Tissue Diseases
30. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial
31. Patency of vascular access ports in minipigs – A success story
32. LY2951742, a monoclonal antibody against CGRP, failed to reduce signs and symptoms of knee osteoarthritis
33. Applications of Bayesian statistical methodology to success criteria: A case study of a phase 2 design with interim futility assessment in patients with knee osteoarthritis
34. Isolation and characterization of further defective clones of a temperature sensitive mutant (ts-1) of respiratory syncytial virus
35. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials
36. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial
37. Viral Replication in Lymphocytes and the Pathogenesis of Connective Tissue Diseases
38. Dual energy X-ray absorptiometry of the knee in spinal cord injury: methodology and correlation with quantitative computed tomography
39. Characterization of osteoarthritis pain variability
40. Bone mineral and stiffness loss at the distal femur and proximal tibia in acute spinal cord injury
41. The Emotional Brain as a Predictor and Amplifier of Chronic Pain.
42. THE NITRIC OXIDE DONATOR NAPROXCINOD HAS BLOOD PRESSURE EFFECTS SIMILAR TO PLACEBO IN PATIENTS ON RENIN-ANGIOTENSIN SYSTEM BLOCKERS: 9D.02
43. EFFECTS OF THE CYCLOOXYGENASE INHIBITING NITRIC OXIDE DONATOR NAPROXCINOD VERSUS NAPROXEN AND IBUPROFEN ON 24-HOUR BP IN PATIENTS WITH OSTEOARTHRITIS AND HYPERTENSION: PP.33.295
44. Correlation of outcome measures and responder identification sensitivity in chronic low back pain: pooled analysis of 2 trials of etoricoxib
45. Change in regional cartilage morphology and joint space width in osteoarthritis participants versus healthy controls: a multicentre study using 3.0 Tesla MRI and Lyon–Schuss radiography
46. (214) Rofecoxib Provides Superior Relief of Pain in Osteoarthritis (OA) Compared to Celecoxib
47. 267 COMPARISON OF EFFICACY OF LUMIRACOXIB 100 MG OD WITH CELECOXIB 200 MG OD IN THE OVERALL POPULATION AND AGE GROUPS <65 AND ≥65: COMBINED ANALYSIS OF TWO PIVOTAL STUDIES IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
48. 260 COMPARISON OF EFFICACY OF LUMIRACOXIB WITH CELECOXIB AND PLACEBO IN KNEE OSTEOARTHRITIS PATIENTS AND DIFFERING BASELINE DISEASE SEVERITY
49. Valve effectively controls amount of contaminant in flow stream
50. 214 POSTER Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor-1 receptor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.